Jones Medical Industries of the USA has completed the acquisition of USfirm Abana Pharmaceuticals. Jones Medical issued an aggregate of around 420,000 shares of its common stock in exchange for the 84% of Abana held by other investors.
Abana markets specialty prescription pharmaceuticals, principally branded generic products used by internists in the treatment of chronic conditions and respiratory ailments. Jones Medical acquired a 16% stake in the company in 1992.
Jones Medical has made 15 strategic acquisitions, four of which were completed in the past 14 months. The Abana deal enhances its physician sales force.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze